Our 2024 Partners
United Immunity
Expertise Partner
United Immunity is developing a Myeloid Targeting Platform™ comprising of Cholesteryl Pullulan (CHP) based nanogels and lipid nanoparticles to target therapeutic payloads (small molecules, mRNA, etc.) to macrophages and dendritic cells for the treatment of cancer, fibrosis, infectious, autoimmune, and inflammatory diseases. UI-102 applies CHP to precisely deliver a TLR7/8 agonist to tumor-associated macrophages and change refractory cold tumors into hot tumors. United's platform is also being applied to T-cell booster vaccines and in vivo CAR-macrophages.
iOmx Therapeutics
Expertise Partner
iOmx is a clinical-stage biotech company that harnesses deep tumour immuno-biology insights along with its proprietary iOTarg™ target screening platform, to generate novel treatments for the most prevalent solid tumour indications.
The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise, iOmx is committed to shaping the future of cancer therapy.
genOway
Expertise Partner
At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Our team of experts brings together decades of experience in designing genetically modified models and a profound understanding of biological physiology to provide unmatched preclinical solutions.
Our collaborative approach, rooted in a deep understanding of your specific needs and complemented by our expertise, strives to define the best solution to predict the success of your research. Join us on a journey of scientific advancement for the benefit of human health.
Immunovive
Exhibition Partner
At Immunovive, we strive to make a difference in the world of immunotherapeutics. Our mission is to accelerate life science research and biologics discovery by providing a premium antibody discovery service rapidly and affordably. Our BinderGenᵀᴹ HTP hybridoma platform generates diverse high-affinity monoclonal antibody binders in 6-8 weeks enabling discovery of critical reagents, therapeutic leads, and substrates for the development of multimodalities. Decades of leadership, expertise, and innovation is applied to each and every project culminating in an optimized research plan designed to deliver high-quality monoclonal antibodies at industry-leading timelines. All operations are conveniently located in the Greater Boston area and our clients retain full ownership of antibodies that we discover together.
Nomic Bio
Event Partner
Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool.
Today we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space.
Our goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic.